• Investors may be wondering whether Thermo Fisher Scientific, at around US$475 per share, still offers value or if most of the opportunity is already priced in.
• The stock is up 14.9% over the past year, even though it is down 19.7% year to date and only slightly higher over the last month. This may have shifted how investors see its risk and reward trade off.
• Recent headlines have focused on Thermo Fisher Scientific's role across pharmaceuticals, biotech and lab tools. This keeps attention on how its scale and product breadth translate into long term cash generation. At the same time, sector wide discussions about funding conditions and healthcare spending have formed part of the backdrop for its mixed shorter term share price performance.
• On Simply Wall St's valuation checks, Thermo Fisher Scientific scores 5 out of 6. The next sections will walk through traditional valuation methods before turning to a broader framework for understanding what that score really means for long term investors.

Approach 1: Thermo Fisher Scientific Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and discounting them back to today using a required rate of return. It is essentially asking what Thermo Fisher Scientific's future cash generation is worth in today's dollars.

Thermo Fisher Scientific's last twelve month Free Cash Flow is about $6.8b. Analysts and Simply Wall St's model project Free Cash Flow rising to $11.4b by 2030, with detailed yearly projections between 2026 and 2035 that are converted into today's dollars using a 2 Stage Free Cash Flow to Equity approach. Analyst estimates cover the earlier years, while the later figures are extrapolated by Simply Wall St.

Adding up these discounted cash flows produces an estimated intrinsic value of about $595.47 per share. Compared with a current share price around $475, the model indicates the stock trades at roughly a 20.1% discount to this DCF estimate, which indicates that Thermo Fisher Scientific stock appears undervalued on this cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Thermo Fisher Scientific is undervalued by 20.1%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Thermo Fisher Scientific Price vs Earnings

For a profitable company, the P/E ratio is a straightforward way to relate what you are paying for each share to the earnings that support it. It gives a quick sense of how many dollars investors are willing to pay today for each dollar of current earnings.

In general, higher growth expectations and lower perceived risk can justify a higher P/E, while slower expected growth or higher risk usually align with a lower, more cautious P/E range. The question is not whether a P/E is high or low in isolation, but whether it fits the company’s earnings profile and risk characteristics.

Thermo Fisher Scientific currently trades on a P/E of 25.81x. This sits below the Life Sciences industry average P/E of 33.86x and also below a peer group average of 40.27x. Simply Wall St’s Fair Ratio model, which estimates an appropriate P/E of 25.62x for Thermo Fisher Scientific, goes a step further by factoring in earnings growth, profit margins, industry, market cap and company specific risks. Because this Fair Ratio is tailored to the company’s fundamentals, it can be more informative than broad industry or peer comparisons. With the actual P/E of 25.81x sitting very close to the Fair Ratio of 25.62x, the stock appears to be priced at about the level this framework would suggest.

Result: ABOUT RIGHT

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Upgrade Your Decision Making: Choose your Thermo Fisher Scientific Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you attach a clear story about Thermo Fisher Scientific to concrete numbers by linking your view of its business, your forecast for revenue, earnings and margins, and your own fair value estimate. You can then compare that to the current price to help decide whether the stock looks attractive or stretched, with the system updating automatically when fresh news or earnings arrive. One investor might align with a higher fair value of about US$720.95 based on stronger growth and an assumed 31.9x future P/E. Another might sit closer to US$520 based on more cautious assumptions and a 28.1x future P/E. A third might prefer the US$611.56 consensus style view. All of these use the same framework but different stories about how Thermo Fisher Scientific could develop over time.

Do you think there's more to the story for Thermo Fisher Scientific? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.